IDF-11774 is primarily used in research settings as a potent and selective inhibitor of the HIF-1α (hypoxia-inducible factor 1-alpha) pathway. It demonstrates significant activity in suppressing tumor growth by disrupting the hypoxic response in cancer cells, which is often associated with resistance to chemotherapy and radiation. Due to its ability to interfere with HIF-1α-dependent gene expression, it is employed in studies focused on angiogenesis, metastasis, and cancer cell survival under low oxygen conditions. Its application extends to preclinical models for evaluating novel anticancer strategies, particularly in solid tumors where hypoxia plays a critical role in disease progression. IDF-11774 is not used clinically but serves as a valuable tool compound in oncology and molecular biology research.